Since few years, sodium-glucose transport (SGLT-2) inhibitors are being considered for T2DM management. Canagliflozin belonging to his category, lowers blood sugar level by causing the kidneys to remove sugar from the body through the urine. It also leads to lowering of blood pressure and making the patients loose 3 to 4 Kg of weight. It is a very useful drug and harmless too when used in T2DM judiciously.
Facts about canagliflozin September 2015: FDA strengthens fracture warning for canagliflozin May 2016: FDA Drug Safety Communication declared increased risk of leg and foot amputations, mostly affecting the toes. May 2017: According to the data from two large clinical trials, US FDA has concluded that the drug causes an increased risk of leg and foot amputations. June 2017: Cardiovascular-outcomes trial data indicated that canagliflozin reduces cardiovascular events by 14% and cuts…
